Cited by 48Cancer Immunotherapy and BiomarkersEndometrial and Cervical Cancer TreatmentsImmunotherapy and Immune Responses

Kinetics of Intratumoral Immune Cell Activation During Chemoradiation for Cervical Cancer

Open access
Dorta-Estremera, Stephanie, Colbert, Lauren E., Nookala, Sita S., Yanamandra, Ananta V., Yang, Guojun, Delgado, Andrea, Mikkelson, Megan, Eifel, Patricia +6 more·2018·International Journal of Radiation Oncology*Biology*Physics

Abstract

Purpose Radiation therapy has direct cytotoxic effects on tumor-infiltrating lymphocytes, but it also has immune stimulatory effects that increase immune cell infiltration. The dynamics of these competing effects on immune cells at the site of the tumor are poorly characterized during chemoradiation treatment (CRT) because of the difficulty of obtaining consecutive tumor biopsies. We used a minimally invasive cervical cytobrushing method to analyze the kinetics of intratumoral immune cell changes in patients with cervical cancer during CRT.Methods and materials Cervical brushings were obtained from 20 patients with cervical cancer at baseline and during fractionated radiation therapy and cisplatin (weeks 1, 3, and 5). Matching peripheral blood mononuclear cells were obtained from 9 patients at the same time points. Cells were analyzed using multispectral flow cytometry to identify T cell and myeloid cell subsets and their activation status. Changes in immune cell subsets throughout treatment were calculated using matched-pair analysis with Wilcoxon rank sum test.Results We observed a significant decline in CD3+ total T cells, as well as CD8+ and CD4+ T-cell subsets in the first week of treatment from baseline, followed by variable expansion at weeks 3 and 5. This coincided with higher levels of proliferating CD8+ T cells expressing Ki67 at week 3 of treatment. The percentages of activated CD8+ T cells expressing CD69 continuously increased over the course of treatment, whereas the percentage of activated CD11c+CD11b- dendritic cells was highest during the first week. Many of these changes were not observed in the blood.Conclusions Our results identified immune dynamic changes during CRT, indicating that CRT may be immune activating at the site of the tumor. This study also suggests the importance of sequential analyses of the local tumor microenvironment in addition to peripheral blood.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ijrobp.2018.06.404

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 24 · Cited by 48

Authors
Dorta-Estremera, S., Colbert, L. E., Nookala, S. S., Yanamandra, A. V., Yang, G., Delgado, A., Mikkelson, M., Eifel, P., Jhingran, A., Lilie, L. L., Welsh, J., Schmeler, K., Sastry, J. K., & Klopp, A.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Klopp, Ann
Venue
International Journal of Radiation Oncology*Biology*Physics
Publisher
Elsevier BV
Published
2018-11
Volume
102
Issue
3
Pages
593-600
ISSN
0360-3016 (ISSN-L)
OpenAlex
W2883440009
Cited by
48
References
24
Citations by year
2026: 3 · 2025: 2 · 2024: 3 · 2023: 15 · 2022: 8 · 2021: 8 · 2020: 7 · 2019: 2
FWCI
1.60
Type
journal article
Language
en
Open access
Locations
  • International Journal of Radiation Oncology*Biology*Physics (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • University of Texas MD Anderson Cancer Center
  • NCI (P30 CA16672)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
cervical cancer, chemoradiotherapy, tumor-infiltrating lymphocytes, CD8+ T cells, CD4+ T cells, dendritic cells, Ki-67, CD69, cisplatin, radiotherapy, tumor microenvironment, T cell proliferation
MeSH terms
Adult, Aged, Biopsy, Uterine Cervical Neoplasms, Cervix Uteri, Dendritic Cells, Female, Flow Cytometry, Humans, Immune System, Immunotherapy, Kinetics, Lymphocyte Activation, Middle Aged, Phenotype, Prospective Studies, Receptors, Antigen, T-Cell, Lymphocytes, Tumor-Infiltrating, CD3 Complex, CD8-Positive T-Lymphocytes, CD11b Antigen, CD11c Antigen, Cell Proliferation, Tumor Microenvironment, Chemoradiotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review